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mTOREnergy deprivation in the myocardium is associated with impaired heart function and increased morbidity.
LKB1 is a kinase that is required for activation of AMP-activated protein kinase (AMPK) as well as 13 AMPK-
related protein kinases. AMPK stimulates ATP production during ischemia and prevents post-ischemic
dysfunction. We used the Cre–Lox system to generate mice where LKB1 was selectively knocked out in
cardiomyocytes and muscle cells (LKB1-KO) to assess the role of LKB1 on cardiac function in these mice.
Heart rates of LKB1-KO mice were reduced and ventricle diameter was increased. Ex vivo, cardiac function
was impaired during aerobic perfusion of isolated working hearts, and recovery of function after ischemia
was reduced. Although oxidative metabolism and mitochondrial function were normal, the AMP/ATP ratio
was increased in LKB1-KO hearts. This was associated with a complete ablation of AMPKα2 activity, and a
stimulation of signaling through the mammalian target of rapamycin. Our results establish a critical role for
LKB1 for normal cardiac function under both aerobic conditions and during recovery after ischemia. Ablation
of LKB1 leads to a decreased cardiac efﬁciency despite normal mitochondrial oxidative metabolism.iology and Metabolism, Joslin
SA.
(L.J. Goodyear).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Mortality from acute myocardial infarction has been reduced
substantially over the last 25 years [32]. However, there has been a
concomitant rise in mortality attributable to heart failure and today
more than 2% of the U.S. population is affected by this condition [18].
Normal cardiac function requires a constant supply of nutrients and
oxygen to generate ATP. Under physiological conditions, 60–70% of
the ATP utilization goes towards the contractile apparatus [29]. When
energy supply is restricted, such as during ischemia, ATP is primarily
used to re-establish Ca2+ ionic homeostasis in an attempt to prevent
ischemic injury [14]. As a result, less ATP is available for contractile
purposes and cardiac power and cardiac efﬁciency are reduced.
The regulation of cardiac ATP metabolism is complex and only
partially elucidated. However, it is well established that the 5′-AMP-
activated protein kinase (AMPK) is necessary for maintaining
myocardial energy homeostasis during ischemia [34]. AMPK is a
serine/threonine kinase that consists of three subunits, α, β and γ. In
the heart, AMPK is phosphorylated and activated by an upstream
kinase LKB1 [25]. LKB1 is a serine/threonine kinase that was originallyidentiﬁed as a tumor suppressor protein, andmore recently, there has
been considerable focus on LKB1 as a regulator of metabolism in liver
and skeletal muscle [11,24,27]. LKB1 functions in a complex with the
two subunits STRAD and MO25. The activity of this complex is not
regulated by ischemia but instead the complex appears to be
constitutively active [25]. In addition to AMPK, LKB1 also phosphor-
ylates 13 of 14 AMPK-related kinases [15]. Unlike AMPK, little is
known about these additional LKB1 substrates, especially in the heart.
AMPK regulates energy metabolism in the heart by phosphorylation
of key enzymes in the energy metabolism pathways. When activated,
AMPK inhibits protein synthesis through regulation ofmammalian target
of rapamycin (mTOR) kinase activity (reviewed in [8]). This preserves
ATP for the contractile apparatus and conserves cardiac function.
Simultaneously, AMPK stimulates ATP production by promoting sub-
strate oxidation [29]. AMPK stimulates glucose uptake by promoting
translocation of the glucose transporter GLUT4 to the cell surface [21].
Fatty acid oxidation is stimulated by phosphorylation of acetyl-
CoAcarboxylase (ACC) [1]. ACC regulates the production of malonyl-
CoA, an allosterical inhibitor of carnitine palmitoyltransferase 1 (CPT-1)
whichcontrols transport of activated fatty acids into themitochondria [1].
The combinedoutcomeofAMPKactivation is consequently stimulationof
oxidative metabolism and inhibition of energy consumption.
Transgenic animals that express a kinase dead AMPK mutant in the
heart have normal cardiac function under aerobic conditions [22,34].
However, when these hearts are subjected to ischemia, ATP regenera-
tion and post-ischemic recovery of cardiac function are dependent on
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normal response to ischemia but is not necessary for normal cardiac
function under aerobic conditions. Less is known about the role of LKB1
in cardiac function. Several LKB1 transgenic mouse models have been
created, a hypomorphic mousemodel wheremuscle LKB1 expression is
completely ablatedwhile LKB1 expression is reduced byﬁve- to ten-fold
in other tissues [25], a muscle and heart-speciﬁc LKB1-KOmousewhere
LKB1 expression is completely ablated only in muscle tissue [11,30,31],
and recently a cardiac-speciﬁc LKB1-KO mouse has been created [9].
Cardiac-speciﬁc LKB1-KO animals die prematurely and have poor
cardiac performance [9], while muscle-speciﬁc LKB1 transgenic mice
survive normally and display no obvious adverse phenotypes [25].
Unlike theAMPK transgenic animals,ACCphosphorylation is profoundly
reduced in hearts from LKB1 transgenic mice [9,25,30] but surprisingly,
malonyl-CoA content is normal in muscle-speciﬁc LKB1-KO hearts [30].
Hearts from the LKB1 hypomorphic mice have increased AMP/ATP
ratios under aerobic conditions [25].Whether this is due to impairments
in substrate oxidation or due to an inability to suppress energy
consuming processes is unknown.
The primary aim of the present study was to investigate the
functional consequences of LKB1 deﬁciency under aerobic and post-
ischemic conditions. In addition,we examined if ablation of LKB1would
affect energy substrate metabolism in the heart. For this purpose we
studied hearts frommice where LKB1was selectively deleted inmuscle
cells using the Cre–Lox system [11]. We found that knock out of LKB1
impairs cardiac function in vivo and ex vivo. Absolute glucose and fatty
acid oxidation rates in LKB1-KO hearts were similar to control hearts,
and mitochondrial function was intact. However, cardiac efﬁciency in
LKB1-KO hearts was impaired. This was associated with increased
activity in the mTOR/p70S6 kinase pathway. These results establish a
critical role for LKB1 in cardiac function and energy metabolism.
2. Materials and methods
2.1. Animals
Muscle and heart-speciﬁc LKB1-KO mice were generated as
described previously [11]. Animals were housed in pathogen-free
facilities, maintained on a 12-hour light cycle, and fed standard
laboratory chow. Ten to twelve week-old mice were used for all
experiments. All experimental procedures were conducted in accor-
dance with NIH guidelines and approved by the Institutional Animal
Care and Use Committee of the Joslin Diabetes Center.
Echocardiography was performed in non-anaesthetised mice with
an Agilent Sonos 4500 ultrasoundmachine and a 12-MHz linear-array
transducer, as previously described [26]. Electrocardiographic inter-
vals were measured in 6 limb leads and 3 pre-cordial leads.
Ventricular pre-excitation was diagnosed on the basis of a short PR
with widened QRS interval.
Control and LKB1-KO mice were subjected to noninvasive physio-
logical and behavioral characterization using the Comprehensive Lab
Animal Monitoring System (CLAMS; Columbus Instruments, Columbus,
OH,USA)at the PhysiologyCore Laboratoryof the JoslinDiabetes Center.
Themiceweremonitored for 24 handassessed for oxygenconsumption
(VO2; ml/kg/h), carbon dioxide generation (VCO2; ml/kg/h), heat
generation calculated from gas exchange data (kcal/h), respiratory
exchange ratio calculated from gas exchange data, food consumption
(grams/24 h), water consumption (ml/24 h), and locomotive activity
evaluated by three-dimensional ﬁxed point observation (counts/h).
Monitoring started at 10:00 h, and CLAMS assessmentwasmade during
both the light cycle (07:00 to 19:00 h) and dark cycle (19:00 to 7:00 h).
2.2. Isolated working mouse heart perfusions
Ex vivo perfused working mouse hearts from control and muscle-
speciﬁc LKB1-KO mice were aerobically perfused as previouslydescribed [12]. Heart rates, pressures, and ﬂows were also deter-
mined, as previously described [12]. Glucose oxidation rates
were determined by measuring 14CO2 released from the metabolism
of [U-14C]glucose, as described [13]. Palmitate oxidation rates were
measured from the release of 3H2O, derived from the metabolism of
[9,10-3H]palmitate, as described [13].
2.3. LKB1 signaling and protein expression
Animals were anaesthetised with i.p. injection of pentobarbital
(100 mg/kg). Hearts were either freeze-clamped in situ at baseline
(basal conditions) or 2 min after cervical dislocation (ischemic condi-
tions), a model previously shown to lead to rapid depletion of ATP and
creatine phosphate in hearts [20].
Whole hearts were homogenized as previously described [7].
Western blot analyses were used to assess expression and phosphor-
ylation levels of various proteins. Blots were developed using ECL
reagents (Amersham, USA), and quantiﬁed using FluorChem 2.01
(Alpha-Innotech-Corporation, USA).
LKB1 and CD36 antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, USA). Antibodies to AMPKα1 and phos-
pho-speciﬁc(Ser79)-ACC antibody were from Upstate (Charlottesville,
USA). GLUT1 and GLUT4 antibodies were from Chemicon (Temecula,
CA). Phospho-speciﬁc AMPK(Thr172), cytochrome C, Akt, phospho-
speciﬁc Akt (Ser473and Thr308), mTOR, phospho-speciﬁc mTOR
(Ser2448), tuberin/TSC and phospho-speciﬁc tuberin/TSC (Thr1426)
antibodies were from Cell Signaling (Beverly, USA). Antibodies to the
beta subunit of ATP synthase were from Abcam (USA). ACC expression
was assessed using HRP-conjugated-streptavidin (Pierce Chemical,
USA). Antibodies to AMPKα2, Malonyl-CoA-Decarboxylase (MCD) and
TRB3 were generated as previously described [5,11,17].
Heart samples were homogenized and AMPKα1 and α2 activity
was assayed as previously described [7,17]. A subset of lysates was
assayed with and without AMP to determine AMP-dependency.
2.4. Citrate synthase activity, ACC activity, nucleotide content and glycogen
measurements
Heart lysates were assayed for citrate synthase activity as
described by Srere [28]. ACC activity was measured in protein lysates
from perfused hearts in the absence or presence of 10 mM citrate as
previously described [23]. AMP and ATP contents were measured
using high-performance liquid chromatography (HPLC) as described
by Merrill et al. [16]. For glycogen measurements, heart muscle was
hydrolyzed in 2 N HCl at 95 °C for 2 h and then neutralized with 2 N
NaOH. Glucose content was measured by a hexokinase method using
a glucose HK reagent (Eagle Diagnostics, Desoto, Texas, USA).
2.5. Statistical analysis
Data are expressed as means±SEM. Normality of the data was
tested with the Kolmogorov–Smirnov test of normal distribution.
Where PN0.20, the datawas considered to be normally distributed. All
normally distributed data were compared using Student's t-test, one-
way or two-way ANOVA. Data that was not normally distributed was
compared using Mann–Whitney Rank Sum Test. The differences
between groups were considered signiﬁcant when Pb0.05.
3. Results
3.1. Creation of muscle-speciﬁc LKB1-KO mice
LKB1 expression in thewhole heart was reduced by 25% and 70% in
heterozygote and LKB1-KO mice, respectively (Fig. 1A). This model is
different from the hypomorphic LKB1 transgenic mouse, where LKB1
expression in all tissues is reduced by ﬁve- to ten-fold [24], and the
Fig. 1. A: There was a 70% reduction in LKB1 expression in LKB1-KO hearts (†: Pb0.01 vs. control, N=8–18). The lox-sites did not affect LKB1 expression and Lox and Lox/+ mice
were used as controls. B: Phosphorylation of AMPK-Thr172 was inhibited in LKB1-KO hearts under both basal and ischemic conditions (a: Pb0.01 vs. basal. *: Pb0.05 vs. control,
N=5–8). C: This was associated with ablated AMPKα2-activity (a: Pb0.01 vs. basal. †: Pb0.01 vs. control, N=5–8) while D: Ischemia increased AMPKα1-activity among all
genotypes (a: Pb0.01 vs. basal, N=5–8). E and F: Knock out of LKB1 increased expression of AMPKα2 and α1 (*: Pb0.05 and †: Pb0.01 vs. control, N=8–18).
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skeletal muscle is normal [9].
Knock out of LKB1 reduced basal and ischemia-induced phosphor-
ylation of AMPKα-Thr172 by ∼90%. AMPK phosphorylation in LKB1
heterozygote hearts was completely normal (Fig. 1B). The decrease in
AMPK phosphorylation corresponded to a complete inhibition of
AMPKα2-activity (Fig. 1C). Thus, knock out of LKB1 fully inhibited
AMPKα2 activity despite a ∼40% increase in expression of the protein.
In contrast to AMPKα2, AMPKα1 activity was conserved in LKB1-KOhearts (Fig. 1D). Furthermore, AMPKα1 activity from ischemic hearts
was assayed±AMP and this showed normal dependency of AMP in all
genotypes (data not shown).
3.2. Heart characteristics
The whole body phenotype of muscle-speciﬁc LKB1-KO animals
has been described previously [11]. LKB1-KOmice did not display any
obvious cardiac phenotype. Spontaneous activity, heart weight and
Table 3
Post-ischemic functional recovery in the aerobically perfused ex vivo working mouse
heart after 20 min of ischemia.
Genotype +/+ −/−
Heart rate (beats min−1) 204±11 177±15
Rate pressure product (bpm mm Hg 10−3) 12±1.0 7±1.3*
Cardiac work (ml mm Hg min−1) 2.0±0.4 0.5±0.4**
Cardiac output (ml/min) 3.3±0.7 0.9±0.6*
Aortic output (ml/min) 1.8±0.5 0.4±0.3
Cardiac power (mJ min−1) 31.2±6.7 5.5±3.9*
Values are mean±SEM, n=7–17, *Pb0.05 vs. control and **Pb0.01.
Table 1
Heart characteristics.
Genotype +/+ −/−
Heart weight (mg) 107.0±5.5 116.6±12.0
Heart weight/body weight (mg/g) 4.2±0.1 4.3±0.2
LV end diastolic diameter (mm) 2.52±0.09 3.36±0.07**
LV end systolic diameter (mm) 0.88±0.1 1.28±0.06*
Fractional shortening 0.65±0.03 0.59±0.02
Heart rate (min−1) 724±19 627±16*
LV anterior wall thickness (mm) 0.86±0.03 0.90±0.02
LV posterior wall thickness (mm) 0.88±0.04 0.94±0.01
AMP/ATP ratio (basal conditions) 0.06±0.01 0.13±0.03*
AMP/AT ratio (ischemic conditions) 0.11±0.03 0.30±0.07*
Glycogen (nmol glucose/g (wet weight) 15.0±1.14 13.3±1.1
Citrate synthase activity (A.U.) 100.0±4.5 93.0±4.7
Cytochrome C expression (A.U.) 100.0±7.3 91.9±6.2
ATP synthase expression (A.U.) 100.0±6.2 97.3±7.5
Values are mean±SEM, n=5–12, *Pb0.05 and **Pb0.01 vs. control.
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control littermates (Table 1). We did not observe enlarged atria in
hearts from the muscle-speciﬁc LKB1-KO mice. Non-anaesthetised
LKB1-KO mice and wild type littermates were evaluated by 2-
dimensional/M-mode echocardiography. Heart rates in LKB1-KO
mice were signiﬁcantly decreased by ∼10%. This was associated
with increased left ventricular systolic diameter and diastolic
diameter. There was a trend for a decreased fractional shortening,
but this did not reach signiﬁcance (Table 1). On electrocardiography
analysis, there was no manifestation of ventricular pre-excitation or
atrial ﬁbrillation observed in any of the mice. There were also no
differences of respiratory exchange ratio between genotypes in both
fasted and fed conditions.
Nucleotide measurements revealed that LKB1-KO hearts were
energy deprived in the basal state (Table 1). We therefore examined
mitochondrial markers, and found that there were no difference in
citrate synthase activity or cytochrome C and ATP synthase β-subunit
expression (Table 1), all suggesting normal mitochondrial function.
3.3. Cardiac function and substrate metabolism in the perfused ex vivo
working mouse heart
To assess the functional consequences of LKB1 deletion in the
heart, we subjected control and LKB1-KO hearts to ex vivo aerobic
perfusions. Similar to the in vivo observations, heart rates were
signiﬁcantly decreased in LKB1-KO hearts (Table 2). This was
associated with an increase in developed pressure resulting in similar
rate pressure product in control and LKB1-KO hearts. Unlike AMPK
transgenic hearts, ablation of LKB1 was associated with an ∼40%
decrease in cardiac output and an ∼30% decrease in cardiac power
under aerobic conditions (Table 2). LKB1 is thus required for normal
cardiac function under aerobic conditions.
To investigate the role of LKB1 in post-ischemic recovery, the
hearts were subjected to 20 min of global ischemia followed by
aerobic reperfusion. LKB1-KO hearts had signiﬁcantly reduced
recovery of function during reperfusion (Table 3). After a 40 min
reperfusion, the rate pressure product was decreased by ∼40% andTable 2
Cardiac function in the aerobically perfused ex vivo working mouse heart.
Genotype +/+ −/−
Heart rate (beats min−1) 285±9 246±17*
Rate pressure product (bpm mm Hg 10−3) 20±0.5 18±0.9
Cardiac work (ml mm Hg min−1) 6.5±0.3 4.2±0.6**
Cardiac output (ml/min) 9.3±0.4 5.8±0.7**
Aortic output (ml/min) 7.1±0.4 3.7±0.8**
Cardiac power (mJ min−1) 71.6±3.3 47.6±7.0**
Values are mean±SEM, n=7–17, *Pb0.05 vs. control and **Pb0.01 vs. control.cardiac output was reduced by ∼70%. Together, these data show that
LKB1 function is required for normal cardiac function under aerobic
conditions and ablation of LKB1 aggravates post-ischemic cardiac
dysfunction.
To determine if the compromised cardiac function in LKB1
deﬁcient hearts was due to impairments in energy substrate
metabolism, we measured fatty acid metabolism. We did not detect
any differences in the expression of the fatty acid transporter protein
CD36 (Fig. 2A). We then determined phosphorylation and activity of
ACC, a key regulator of malonyl-CoA production and fatty acid
oxidation. The expression of ACC was similar among genotypes. In the
basal state, ACC phosphorylation was reduced by 81% in LKB1-KO
hearts while no difference was observed in heterozygote hearts
(Fig. 2B). During ischemia, ACC was phosphorylated in hearts from
control and heterozygote animals, but in LKB1-KO hearts ACC
phosphorylation was decreased by 85%. However, these differences
in ACC phosphorylation did not translate into changes in ACC activity
between knock out and control hearts (Fig. 2C). We next measured
MCD expression, the key enzyme involved in malonyl-CoA decarbox-
ylation. In LKB1-KO hearts MCD protein expression was decreased by
∼70% (Fig. 2D). However, despite reduced MCD expression, fatty acid
oxidation rates were similar between LKB1-KO and control animals
(Fig. 3A).
We next looked at glucose metabolism. In the basal state, glycogen
levels were similar in LKB1-KO and control hearts (Table 1). Similar to
CD36, expression of the glucose transporters GLUT1 and GLUT4 were
normal in LKB1-KO hearts (data not shown). When glucose oxidation
rates were measured ex vivo, we did not detect any differences
between LKB1-KO and control hearts (Fig. 3B). From these data, TCA
cycle acetyl-CoA production was calculated and these data show that
the impaired cardiac function in LKB1-KO hearts was not due to
impaired oxidative metabolism (Fig. 3C).
3.4. Mammalian target of rapamycin (mTOR) signaling
Measurements of oxidative metabolism did not provide an
explanation for the impaired cardiac function.We therefore examined
the regulation of energy consuming processes. When activated, AMPK
inhibits protein synthesis and this process is impaired in cardiac-
speciﬁc LKB1-KO hearts [9]. Consequently, we investigated signaling
through mTOR, a master regulator of protein synthesis in the heart.
Knock out of LKB1 increased cardiac mTOR protein expression by ∼3
fold (Fig. 4A) and phosphorylation on the activating Ser2448 site by ∼8
fold in the basal state with no further activation during ischemia
(Fig. 4A). This was associated with increased phosphorylation of the
downstream targets p70S6 kinase and 4E-BP1 without changes in
protein expression (Fig. 4B,C). Since insulin stimulates mTOR Ser2448
phosphorylation through Akt and tuberin/TSC2 phosphorylation, we
investigated if these proteins were activated in LKB1-KO hearts.
Interestingly, Akt2 expression was increased in LKB1-KO hearts by ∼2
fold (Fig. 4E). Unlike skeletal muscle [11], this was not associated with
decreased expression of TRB3 (data not shown). However, the
increased Akt2 expression did not translate into increased phosphor-
ylation of Akt on Ser473 and Thr408 (Fig. 4D,E) and no changes in
Fig. 3. A and B: Knock out of LKB1did not affect rates of glucose and palmitate oxidation or
total during aerobic perfusion or reperfusion (†: Pb0.01 vs. corresponding aerobic control
group, N=7–11). C: Knock out of LKB1 also did not affect total tricarboxylic acid cycle
acetyl-CoA production (†: Pb0.01 vs. corresponding aerobic control group, N=5–12).
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Together these data show that ablation of LKB1 results in activation of
mTOR in cardiomyocytes independently of Akt.
4. Discussion
Our results establish that LKB1 is necessary for normal cardiac
function. In vivo, therewas limited cardiac dysfunction in the LKB1-KO
mice. Heart rates were lower and ventricles were dilated, but
fractional shortening was not signiﬁcantly reduced. However, ex
vivo, the heart was not able to compensate for the ablation of LKB1Fig. 2. A: Knock out of LKB1 did not affect expression of the fatty acid transporter
protein CD36 (N=11–12). B: Phosphorylation of ACC was blunted in LKB1-KO hearts
during both basal and ischemic conditions (a: Pb0.01, b: Pb0.05 vs. basal. *: Pb0.05 vs.
control, N=6–8). ACC protein expression was similar among genotypes. C: The activity
of ACC was measured in the presence or absence of 10 mM citrate in protein lysates
from perfused hearts after reperfusion. There were no differences in activity among
genotypes (N=5–6). D: Expression of MCD was reduced by ∼70% in LKB1-KO hearts
(Pb0.05 vs. control (N=6).
Fig. 4. A: Akt/mTOR/p70S6K signaling. A: Ablation of LKB1 increasedmTOR Ser2448 phosphorylation independently of ischemia. B and C: The increasedmTOR activity was associated
with increased phosphorylation of p70S6 kinase and 4E-BP1. (*: Pb0.05, †: Pb0.01 vs. control, N=4–12). D and E: Knock out of LKB1 did not increase Akt phosphorylation or F: Akt
signaling to the downstream target tuberin/TSC2.
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sion. The impaired cardiac function was associated with an increased
AMP/ATP ratio and decreased cardiac efﬁciency. This may provide the
explanation for the impaired cardiac function since reductions in ATP
availability impair contractile function and leave the hearts suscep-
tible to ischemic injury. Indeed, when LKB1-KO hearts were subjected
to ischemia ex vivo cardiac dysfunction was further aggravated.
Whether this was a consequence of the poor function at baseline or
if LKB1-KO hearts have a speciﬁc impairment in the response to
ischemia remains to be investigated.
Deﬁciency of LKB1 resulted in up-regulation of mTOR/p70S6K
signaling, suggesting an impaired ability to attenuate protein
synthesis in these mice. The increased mTOR signaling was associated
with a tendency for increased ventricle wall thickness and heart
weights in our LKB1-KO animals, consistent with the mild [30] or
more pronounced hypertrophy observed in other LKB1 genetic
models [9,19,33]. However, unlike the cardiac-speciﬁc LKB1-KO
model [9] we did not observe the severe morphometric phenotype
with biatrial enlargement or atrial ﬁbrillation in the muscle-speciﬁc
LKB1-KO model. The mechanism for the increased mTOR signaling is
not fully understood, but is likely due to the ablated AMPKα2 activity.
AMPK can directly phosphorylate mTOR on Thr2446 [3] and tuberin/
TSC2 [10] and thereby inhibit phosphorylation of the activating
Ser2448 site on mTOR. If mTOR and tuberin/TSC2 phosphorylation are
solely mediated through AMPKα2 and not AMPKα1 then this
provides the mechanism by which knock out of LKB1 can increase
mTOR signaling. Alternatively, one or more of the AMPK-related
kinases may be involved in the regulation of mTOR activity. Impaired
ability to suppress the energy consuming processes regulated by
mTORwould render less energy available for contractile purposes and
provide explanation for the cardiac dysfunction in LKB1-KO hearts.
In vivo, we only observed a modest cardiac dysfunction, as
evidenced by a decreased heart rate but normal fractional shortening,
and this indicates that the ventricle maintained normal cardiac output
by the Frank–Sterling mechanism. The echocardiographs were
performed in awake mice and the stress from the procedure may
have caused an elevation in catecholamines, which could have
impaired the ability to detect left ventricular dysfunction. However,
knock out of LKB1 did not reduce activity levels in the non-stressed
environment of our Comprehensive Lab Animal Monitoring System
(CLAMS). This does not exclude that under situations with more
severe cardiac stress the compensation may be inadequate. Indeed,
when LKB1-KO mice are challenged by exercise, voluntary running
performance is signiﬁcantly reduced (Koh and Goodyear unpublished
observations and [31]), although this effect can be due to ablation of
LKB1 in skeletal muscle, the heart or a combination of both. However,
the data obtained from the muscle-speciﬁc LKB1-KOmice are not due
to overt differences in activity levels.
Under non-ischemic conditions almost all (N95%) of ATP formation
in the heart comes from oxidative metabolism in the mitochondria
[29]. However, the compromised cardiac function in LKB1-KO hearts
was not associated with reductions in oxidative rates or impaired
mitochondrial function. The impaired cardiac function and increased
AMP/ATP ratio therefore do not appear to be caused by an inhibition
of ATP production. AMPK has been suggested to play a major role in
the regulation of metabolism in the heart through the regulation of
malonyl-CoA levels [29]. ACC was one of the ﬁrst identiﬁed substrates
of AMPK [2] and our data conﬁrm that in the heart phosphorylation of
ACC on Ser79 is dependent on AMPKα2 activity. However, the reduced
phosphorylation of ACC did not translate into changes in ACC activity
and we did not observe decreased palmitate oxidation. ACC activity
was measured at the end of the reperfusion period where no ACC
phosphorylation could be detected in the LKB1-KO hearts. This
observation is in agreement with the previous reports that demon-
strate thatmalonyl-CoA levels in LKB1-KO hearts are similar to control
hearts [30]. It is therefore clear that while ACC Ser79 phosphorylationcan be used as an important marker of AMPKα2 activity it cannot be
directly translated into changes in fatty acid oxidation in the heart.
The exact explanation for the dissociation between ACC phosphory-
lation and activity is unknown. However, recent reports on the crystal
structure of ACC have revealed that phosphorylation of ACC by AMPK
disrupts the formation of active ACC polymers [4]. Whether
alternative mechanisms to ACC phosphorylation can disrupt the
formation of ACC polymers in LKB1-KO hearts is a topic of further
investigation.
In contrast to AMPKα2, AMPKα1 activity was conserved in our
LKB1-KO hearts. Similar observations have been made in the LKB1
hypomorphic mouse and have led to speculation as to whether theα1
subunit is solely expressed in non cardiomyocytes [25]. However,
muscle-speciﬁc knock out of LKB1 increases expression of AMPKα1 by
∼50% in the heart. This effect could be a compensatory mechanism for
the ablated α2 activity and would therefore indicate that the α1-
subunit is indeed expressed in cardiomyocytes. If AMPKα1 is
expressed in cardiomyocytes, the activity is regulated differently
from AMPKα2 and is not dependent on LKB1 expression.
In conclusion, our ﬁndings demonstrate that LKB1 function is
essential for normal contractile function in the heart. Ablation of the
protein leads to decreased cardiac output under aerobic conditions
and this functional defect is further aggregated after LKB1-KO hearts
have been subjected to ischemia. The compromised cardiac function is
not due to impaired oxidative metabolism but is associated with
increased mTOR signaling and may thus be due to an impaired ability
to suppress energy consuming processes.Acknowledgements
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